Twist Bioscience Corporation has priced an underwritten public offering of its common stock, upsized to $300 million in gross proceeds. The company is selling 3.12 million shares at $96.00 per share, with underwriters granted a 30-day option to purchase up to an additional 468,750 shares. The offering is expected to close on August 6, 2026, and proceeds will fund research and development, manufacturing expansion, and general corporate purposes. Goldman Sachs, William Blair, Leerink Partners, and Guggenheim Securities are acting as joint book-running managers.
Twist Bioscience CorpCompany is selling shares in an upsized offering, diluting existing shareholders.
